Neurodegenerative Disease Investment: Shifting Paradigms Beyond Amyloid And Tau

Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.